HF Treatment According to COPD Therapy for Patients With HF and COPD Diagnoses
| HF treatment | Total | ||||
|---|---|---|---|---|---|
| COPD therapy groups* for patients with COPD and HF | None | ARB and/or ACEI | β-blocker only | β-blocker and ACEI and/or ARB | |
| SABA or SAMA only, n (%) | 639 (32.1) | 814 (40.8) | 115 (5.8) | 426 (21.4) | 1994 (100) |
| LABA or LAMA, n (%) | 218 (21.0) | 407 (39.2) | 60 (5.8) | 354 (34.1) | 1039 (100) |
| LABA+ICS, n (%) | 757 (26.6) | 1367 (48.0) | 140 (4.9) | 583 (20.5) | 2847 (100) |
| LABA+LAMA, n (%) | 18 (17.1) | 43 (41.0) | 7 (6.7) | 37 (35.2) | 105 (100) |
| LAMA+ICS, n (%) | 26 (15.6) | 79 (47.3) | 6 (3.6) | 56 (33.5) | 167 (100) |
| LABA+LAMA+ICS, n (%) | 559 (19.7) | 1316 (46.5) | 180 (6.4) | 778 (27.5) | 2833 (100) |
| ICS only, n (%) | 754 (42.0) | 816 (45.5) | 45 (2.5) | 179 (10.0) | 1794 (100) |
*Considering SABA, SAMA, LABA, LAMA and ICS prescriptions only.
ACEI, ACE inhibitor; ARB, angiotensin-2 receptor blockers; COPD, chronic obstructive pulmonary disease; HF, heart failure; ICS, inhaled corticosteroid; LABA, long-acting β-agonist; LAMA, long-acting muscarinic antagonist; SABA, short-acting β-agonist; SAMA, short-acting muscarinic antagonist.